(2R,3R)-3-tert-Butoxycarbonylamino-2-(3-cyano-benzyl)-5-phenyl-pentanoic acid methyl ester | 193153-19-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (2R,3R)-3-tert-Butoxycarbonylamino-2-(3-cyano-benzyl)-5-phenyl-pentanoic acid methyl ester
• CAS: 193153-19-4
• 化学式: C₂₅H₃₀N₂O₄
• 分子量: 422.524
• InChiKey: MFLMZFRUKAACTR-FGZHOGPDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.42
• 重原子数：
  31.0
• 可旋转键数：
  8.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  88.42
• 氢给体数：
  1.0
• 氢受体数：
  5.0

反应信息

• 作为反应物：
  描述：

  (2R,3R)-3-tert-Butoxycarbonylamino-2-(3-cyano-benzyl)-5-phenyl-pentanoic acid methyl ester 在 吡啶 、 硫化氢 、 ammonium acetate 、 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 三乙胺 、 三氟乙酸 、 碘甲烷 作用下， 以 二氯甲烷 为溶剂， 反应 2.03h， 生成 (2R,3R)-3-[(Biphenyl-4-carbonyl)-amino]-2-(3-carbamimidoyl-benzyl)-5-phenyl-pentanoic acid methyl ester
  参考文献：
  名称：

  Identification and Initial Structure−Activity Relationships of a Novel Class of Nonpeptide Inhibitors of Blood Coagulation Factor Xa

  摘要：

  The discovery and some of the basic structure-activity relationships of a series of novel nonpeptide inhibitors of blood coagulation Factor Xa is described. These inhibitors are functionalized p-alanines, exemplified by 2a. Docking experiments placing 2a in the active site of Factor Xa implied that the Most expeditious route to enhancing in vitro potency was to modify the group occupying the S3 site of the enzyme. Increasing the hydrophobic contacts between the inhibitor and the enzyme in this region led to 8, which has served as the prototype for this series. In addition, an enantioselective synthesis of these substituted p-alanines was also developed.

  DOI：

  10.1021/jm970482y
• 作为产物：
  描述：

  在 silver benzoate 、 三乙胺 、 lithium hexamethyldisilazane 作用下， 反应 2.75h， 生成 (2R,3R)-3-tert-Butoxycarbonylamino-2-(3-cyano-benzyl)-5-phenyl-pentanoic acid methyl ester
  参考文献：
  名称：

  Identification and Initial Structure−Activity Relationships of a Novel Class of Nonpeptide Inhibitors of Blood Coagulation Factor Xa

  摘要：

  The discovery and some of the basic structure-activity relationships of a series of novel nonpeptide inhibitors of blood coagulation Factor Xa is described. These inhibitors are functionalized p-alanines, exemplified by 2a. Docking experiments placing 2a in the active site of Factor Xa implied that the Most expeditious route to enhancing in vitro potency was to modify the group occupying the S3 site of the enzyme. Increasing the hydrophobic contacts between the inhibitor and the enzyme in this region led to 8, which has served as the prototype for this series. In addition, an enantioselective synthesis of these substituted p-alanines was also developed.

  DOI：

  10.1021/jm970482y